LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Search

Denali Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

21.05 -1.73

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

20.04

Max

21.32

Schlüsselkennzahlen

By Trading Economics

Einkommen

-2.8M

-127M

Angestellte

517

EBITDA

-12M

-134M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+51.45% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

4. März 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1B

3.3B

Vorheriger Eröffnungskurs

22.78

Vorheriger Schlusskurs

21.05

Nachrichtenstimmung

By Acuity

60%

40%

284 / 352 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Denali Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Feb. 2026, 23:53 UTC

Heiße Aktien

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27. Feb. 2026, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

27. Feb. 2026, 17:55 UTC

Heiße Aktien

Toronto Stocks Decline, But Remain On Track for Weekly Gains

27. Feb. 2026, 23:46 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27. Feb. 2026, 23:33 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27. Feb. 2026, 21:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

27. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27. Feb. 2026, 21:30 UTC

Ergebnisse

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27. Feb. 2026, 21:30 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27. Feb. 2026, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27. Feb. 2026, 21:17 UTC

Ergebnisse

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27. Feb. 2026, 21:10 UTC

Akquisitionen, Fusionen, Übernahmen

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27. Feb. 2026, 21:09 UTC

Akquisitionen, Fusionen, Übernahmen

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27. Feb. 2026, 21:00 UTC

Ergebnisse

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27. Feb. 2026, 20:31 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27. Feb. 2026, 20:24 UTC

Market Talk

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27. Feb. 2026, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27. Feb. 2026, 20:12 UTC

Market Talk

Nike Seen With Further Challenges in China -- Market Talk

27. Feb. 2026, 19:44 UTC

Market Talk

Gold Caps Historic Month -- Market Talk

27. Feb. 2026, 19:39 UTC

Ergebnisse

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27. Feb. 2026, 19:38 UTC

Ergebnisse

Earnings Could Push the Stock Market Higher. Too Bad About Everything Else. -- Barrons.com

27. Feb. 2026, 18:53 UTC

Akquisitionen, Fusionen, Übernahmen

Largest U.S. Pension Takes Stake in a Hot Semi Stock, Buys More Nvidia and IonQ -- Barrons.com

27. Feb. 2026, 18:45 UTC

Ergebnisse

Quantum Computing Is No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

27. Feb. 2026, 18:45 UTC

Market Talk

Bitcoin Stays Vulnerable in Choppy Geopolitical Situation -- Market Talk

27. Feb. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

27. Feb. 2026, 17:07 UTC

Ergebnisse

Pemex Cuts 4Q Loss As Operating Results Improve

27. Feb. 2026, 17:00 UTC

Market Talk

Corn Rides Oil Momentum Higher -- Market Talk

27. Feb. 2026, 16:31 UTC

Market Talk

Canadian Economy Shows Resilience -- Market Talk

27. Feb. 2026, 16:17 UTC

Market Talk

Canada Economy is Struggling But More Rate Cuts Still a Long Shot -- Market Talk

27. Feb. 2026, 15:49 UTC

Ergebnisse

Quantum Computing No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

Peer-Vergleich

Kursveränderung

Denali Therapeutics Inc Prognose

Kursziel

By TipRanks

51.45% Vorteil

12-Monats-Prognose

Durchschnitt 32.44 USD  51.45%

Hoch 40 USD

Tief 25 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Denali Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

12 ratings

11

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

13.355 / 16.44Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Neutral Evidence

Langfristig

Strong Bearish Evidence

Stimmung

By Acuity

284 / 352 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat